{"id":8152,"date":"2026-11-12T15:48:57","date_gmt":"2026-11-12T14:48:57","guid":{"rendered":"https:\/\/mykolab.eu\/?p=8152"},"modified":"2026-11-12T15:48:57","modified_gmt":"2026-11-12T14:48:57","slug":"women-and-psilocybin-research","status":"publish","type":"post","link":"https:\/\/mykolab.eu\/es\/women-and-psilocybin-research\/","title":{"rendered":"Women and Psilocybin Research: Which Questions Are Scientists Asking?"},"content":{"rendered":"\n
Headlines about psilocybin tend to focus on a striking possibility: a psychedelic experience might help ease depression. For women reading those stories, the questions can feel more personal. Could this research eventually offer something to someone struggling after childbirth? What about the changes in mood and sleep that can accompany menopause? And does the research tell us whether women experience psilocybin differently from men?<\/p>\n\n\n\n
Scientists are exploring these questions, although some are much further along than others. Depression studies have already included women, while research focused on menopause and the months after childbirth is still at an earlier stage. Looking beyond the headlines reveals both interesting findings and gaps that matter in everyday life.<\/p>\n\n\n\n
Psilocybin and depression: what have researchers discovered?<\/h2>\n\n\n\n
Studies suggest that psilocybin, given with psychological support, can reduce symptoms of depression in some adults. Women have taken part in these trials, but researchers still have more to learn about whether their responses differ from men\u2019s.<\/p>\n\n\n\n
One study published in JAMA<\/em> in 2023 included 104 adults with depression, half of whom were women. Participants received either a single 25-mg dose of psilocybin or a comparison substance, alongside psychological support. The psilocybin group showed a greater reduction in depression scores by day 43, around six weeks after treatment. These were results for the whole group, rather than a separate finding about effectiveness in women.<\/p>\n\n\n\n
The care surrounding the experience is part of the story. Participants were screened beforehand and supported before, during and after the session. This makes the findings different from claims about taking mushrooms independently or following a microdosing routine.<\/p>\n\n\n\n
Side effects also occurred. Headaches and nausea were more common with psilocybin, and some reactions were intense. No treatment-emergent events met the study\u2019s definition of a serious adverse event, but that does not mean every participant had an easy experience.<\/p>\n\n\n\n
Could the menstrual cycle make a difference?<\/h3>\n\n\n\n
This is one of the questions researchers are beginning to examine. A study plan published in 2026 describes an investigation involving 21 healthy participants who menstruate. Researchers aim to compare their responses to low-dose psilocybin at different points in the menstrual cycle, including how they feel and how their bodies process the substance. Results were not included in that publication.<\/p>\n\n\n\n
The question is easy to understand: could the same person respond differently at different times of the month? Answering it could help future studies pay closer attention to women\u2019s experiences, rather than treating the menstrual cycle as background information.<\/p>\n\n\n\n
Could psilocybin help with postpartum depression?<\/h2>\n\n\n\n
Research into depression naturally raises questions about women struggling after childbirth. However, psilocybin has not yet been established as a safe and effective treatment for postpartum depression, and findings from other depression studies cannot simply be carried over.<\/p>\n\n\n\n
The months after giving birth bring a particular set of research questions. Scientists need to consider how a treatment affects a mother\u2019s mood and ability to care for her baby, as well as whether a breastfed infant could be exposed to the substance. Feeling better on a depression questionnaire is only one part of that picture.<\/p>\n\n\n\n
Some early studies have explored other psychedelics for postpartum depression. One small study involving ten women reported rapid improvements in symptoms, but everyone received the treatment and knew they were receiving it. Without a comparison group, it is difficult to know how much of the improvement came from the substance itself. The study also did not test psilocybin.<\/p>\n\n\n\n
There are reasons to investigate safety carefully. In a 2025 study involving mice, psilocybin did not improve the stress-related behaviours researchers were examining in mothers. Some later effects in the mothers and offspring were harmful. Animal findings cannot predict exactly what will happen in people, but they show why the period after childbirth needs its own research.<\/p>\n\n\n\n
For a reader following this topic, the distinction matters: interest in a possible treatment is not the same as evidence that it is ready to use. Women experiencing postpartum depression should seek professional support rather than try to treat themselves with psilocybin.<\/p>\n\n\n\n
Psilocybin and menopause: why are researchers interested?<\/h2>\n\n\n\n
Mood, sleep and physical symptoms are all part of the discussion around psilocybin and menopause. Researchers are interested in whether psychedelics might help with some of these difficulties, but dedicated controlled studies are still lacking.<\/p>\n\n\n\n
One project run by Hystelica follows women in perimenopause, the transition towards menopause, or after menopause who have already decided to microdose psychedelics. Over 12 weeks, participants answer questions about their mental and physical symptoms. Researchers do not provide the substances or tell participants how to take them. The project follows people\u2019s experiences; it is not a trial assigning psilocybin as a treatment.<\/p>\n\n\n\n
This kind of research can help identify patterns worth exploring. If participants report better sleep, for example, researchers can investigate that more closely in a future study. It cannot, by itself, show that microdosing caused the improvement. Symptoms may change over time, and other treatments or expectations may also play a part.<\/p>\n\n\n\n
It also helps to ask what \u201cfeeling better\u201d actually means. Improved mood, fewer hot flushes and more restful sleep are different outcomes. Evidence for one would not automatically establish benefits for the others.<\/p>\n\n\n\n
Could hormones affect the experience?<\/h3>\n\n\n\n
Scientists think this is possible, but direct evidence remains limited. Hormones may influence serotonin signalling, one of the systems involved in psychedelic effects. Researchers have proposed that these changes could affect responses to psychedelics, although they have not established whether menopausal hormone therapy changes the effects of psilocybin.<\/p>\n\n\n\n
There is a practical reason to explore this. A woman with regular menstrual cycles, someone going through perimenopause and someone years beyond menopause may have different hormonal circumstances. Future research needs to account for those differences before drawing conclusions about women as a whole.<\/p>\n\n\n\n
For now, stories about psilocybin easing menopause symptoms are ahead of the clinical evidence. They may inspire research questions, but they do not yet provide reliable answers about benefits or safety.<\/p>\n\n\n\n
Meditation and mushroom use: what does the wider picture show?<\/h2>\n\n\n\n
Research on psilocybin also extends beyond medical treatment. Scientists have studied how it affects meditation experiences, while European surveys offer a glimpse of how many women and men report using psychedelic mushrooms. These findings add context, although neither tells us that psilocybin has a particular effect on women.<\/p>\n\n\n\n
A 2019 study followed 39 experienced meditators during a five-day mindfulness retreat. Compared with participants who received a placebo, those given psilocybin reported deeper meditation experiences. Researchers also recorded greater improvements in mindfulness and aspects of everyday psychological and social functioning at follow-up. The group included women and men, and the study did not establish a separate benefit for women.<\/p>\n\n\n\n
What makes this research interesting is the attention it gives to the setting. The participants already knew how to meditate and were taking part in a structured retreat. Their experience cannot tell us what would happen to a beginner trying to combine meditation with a psychedelic at home.<\/p>\n\n\n\n
Do women use psychedelic mushrooms less often than men?<\/h3>\n\n\n\n
Some European data suggest that fewer women report having tried them, although the difference depends on the period being measured.<\/p>\n\n\n\n
Spain\u2019s EDADES 2024 survey asked people aged 15\u201364 about drug use, including a separate category for \u201cmagic mushrooms\u201d. Its statistical tables report the following:<\/p>\n\n\n\n
Reported magic mushroom use in Spain<\/th>
Men<\/th>
Women<\/th><\/tr><\/thead>
At least once in their lifetime<\/strong><\/td>
4.4%<\/td>
2.0%<\/td><\/tr>
During the previous 12 months<\/strong><\/td>
0.4%<\/td>
0.3%<\/td><\/tr><\/tbody><\/table>Source: EDADES 2024 results in OEDA\u2019s 2025 report, Tables 13 and 14. The figures above follow the statistical tables; the report\u2019s narrative section gives a different female lifetime figure of 2.2%.<\/figcaption><\/figure>\n\n\n\n
The lifetime figures suggest that men were about 2.2 times as likely to report having tried mushrooms. Yet the previous-year estimates were much closer. That makes the answer more interesting than a simple claim that mushroom use is mainly a male activity.<\/p>\n\n\n\n
These percentages describe how many people reported use, rather than how often they used mushrooms or why they took them. They also come from one country, so they should not be treated as a picture of all European women.<\/p>\n\n\n\n
For anyone curious about women and psilocybin, the most useful research will connect these broader patterns with more specific questions. Does reproductive stage influence the response? Which symptoms might improve? How long could benefits last, and what risks need attention? Those are the questions that will make future findings more relevant to women\u2019s lives.<\/p>\n\n\n\n
This article explores scientific research and is not a guide to self-treatment. If you are experiencing depression or other mental health difficulties, speak with a qualified healthcare professional.<\/em><\/p>\n\n\n\n
Article author<\/h2>\n\n\n\n
Piotr Kwiatkowski<\/strong> is the founder of MYKOLAB and a self-taught mycology enthusiast who has been developing his knowledge through hands-on practice and personal experiments since 2020. In February 2022, he turned his interest in fungi into a professional business by founding a company that produces mushroom grow kits.<\/p>\n\n\n\n
Today, he runs a 550 m\u00b2 production facility, and his company has produced tens of thousands of mushroom grow kits for individual customers and international business partners. His work focuses on developing proprietary technologies, maintaining production quality and consistency, and making mushroom cultivation simpler.<\/p>\n\n\n\n